Skip to main content

Table 2 Comparison of dosimetric results for 3DCRT and VMAT plans

From: Can advanced new radiation therapy technologies improve outcome of high grade glioma (HGG) patients? analysis of 3D-conformal radiotherapy (3DCRT) versus volumetric-modulated arc therapy (VMAT) in patients treated with surgery, concomitant and adjuvant chemo-radiotherapy

 

3DCRT

VMAT

P

PTV

 V95 % (%)

93.6 ± 10.2 [52.5; 100.0]

97.2 ± 21.8 [32.4; 99.8]

ns

 V107 % (%)

0.5 ± 0.9 [0; 2.8]

0.1 ± 0.3 [0.0; 1.4]

ns

 Vol (cm3)

203.1 ± 101.4 [91.2; 490.8]

274.8 ± 112.9 [99.6; 507.7]

ns

 D99 % (%)

85.4 ± 19.7 [4.37; 97.30]

82.8 ± 23.7 [16.8; 97.2]

ns

 HI

0.13 ± 0.8 [0.04; 1.21]

0.09 ± 0.04 [0.03; 0.50]

0.04

 CI

1.40 ± 0.30 [1.02; 2.09]

1.04 ± 0.02 [1.00; 1.09]

<0.01

Brain-PTV

 V3Gy(%)

75.0 ± 18.1 [42.0; 100.0]

79.9 ± 14.8 [51.9; 99.4]

ns

 V5Gy (%)

69.3 ± 18.1 [42.0; 100.0]

72.9 ± 16.3 [46.6; 98.0]

ns

 V20Gy (%)

35.4 ± 16.1 [14.2; 75.5]

32.6 ± 13.3 [13.9; 53.7]

ns

 V35Gy (%)

21.6 ± 12.6 [3.5; 48.9]

12.1 ± 5.6 [5.1; 24.1]

0.03

 Dmean (Gy)

18.8 ± 7.0 [10.8; 66.4]

16.5 ± 4.8 [9.9; 24.9]

ns

 D1 % (Gy)

58.9 ± 5.1 [39.9; 65.3]

55.9 ± 1.8 [53.4; 59.3]

ns

Ipsilateral Lens

 D1 % (Gy)

6.4 ± 4.5 [0.5; 14.9]

5.3 ± 2.8 [0.6; 13.9]

ns

Controlateral Lens

 D1 % (Gy)

3.6 ± 4.9 [0.4; 19.8]

5.1 ± 4.2 [0.7; 21.1]

ns

Ipsilateral Optic Nerve

 D1 % (Gy)

19.6 ± 19.2 [1.0; 57.2]

25.5 ± 18.2 [0.9; 53.7]

ns

Controlateral Optic Nerve

 D1 % (Gy)

10.1 ± 11.7 [0.7; 47.2]

12.9 ± 8.9 [1.3; 36.6]

ns

Chiasm

 D1 % (Gy)

22.2 ± 18.1 [1.4; 56.7]

32.0 ± 18.6 [1.8; 55.9]

0.02

Brainstem

 D1 % (Gy)

33.5 ± 18.4 [1.7; 57.3]

40.9 ± 18.0 [4.9; 62.5]

0.04